Evaluating Different Medications Used in the Treatment of Polycystic Ovarian Syndrome in Tikrit City Women.

Abstract

Background: One of the most common endocrine disorders that impacts reproductive-aged women is Polycystic Ovary Syndrome (PCOS). There are various pharmacological agents used to manage the condition, such as antiandrogens, aromatase inhibitors, metformin, thiazolidinediones, and ovulation-inducing medications. Such medications focus on increasing insulin sensitivity and restoring ovulatory function. The clinical characterizations of polycystic ovary syndrome include hyperandrogenism, menstrual irregularities, and polycystic ovarian morphology.
Objectives: The objective of this research is to estimate the effectiveness of different medications on the signs and symptoms of polycystic ovary syndrome.
Methods: From October to December 2024, a cross-sectional study was performed on 204 women in Iraq aged between 15 and 45 years to assess the therapeutic practices for PCOS. To acquire the relevant data, private gynecological consultations were held, including laboratory measurements and a questionnaire, which were analyzed using Microsoft Excel 2021.
Results: The findings showed that the commonly-prescribed medications are Metformin (35.2%) and Diane 35 (34.8%). Furthermore, menstrual interruptions, hirsutism, and acne were the most commonly reported symptoms. Hormonal evaluations show that there was heterogeneity between participants, especially regarding the levels of androgen and reproductive hormones. The findings are reflective of typical polycystic ovary syndrome clinical manifestations and the personalized pharmacological approaches used to manage symptoms and regulate hormones.
Conclusions: Polycystic ovary syndrome is an intricate condition that can have different manifestations, including menstrual irregularities, obesity, acne, and hirsutism. Moreover, it can have significant metabolic and psychological implications. Despite being the most commonly administered drugs for the condition, Diane-35 and Metformin were found to impact quality of life. In turn, this highlights the need to develop treatment approaches that integrate pharmacological management with lifestyle changes in order to achieve the best possible outcomes.